Keppra I.V. Formulation Is “Approvable” In U.S., Gains Positive EMEA Opinion
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised labeling for antiepileptic, manufacturing information requested by FDA already submitted, firm says.